Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 9 pages · English
Bio-Gene Technology Ltd. on 6ix
Earlier from Bio-Gene Technology
- U.S. Department of Defense Grant Programs Advance
- Bio-Gene Receives $519,500 R&D Tax Incentive
- CEO's Presentation
- Chair's Address to Shareholders
- Qcide receives organic listing status in USA
Later from Bio-Gene Technology
- Appendix 4D and Half-Year Accounts 31 December 2025
- Regulatory Development of Flavocide
- Sumitomo & Nakashima to launch Qcide products in Japan
- Results of Placement
- Appendix 4E and 2026 Annual Report
Follow Bio-Gene Technology into a list and get an email when it puts out news.
Follow Bio-Gene Technology